Steven Jon Russell - Jan 29, 2025 Form 3 Insider Report for Beta Bionics, Inc. (BBNX)

Role
Chief Medical Officer
Signature
/s/ Stephen Feider, Attorney-in-Fact
Stock symbol
BBNX
Transactions as of
Jan 29, 2025
Transactions value $
$0
Form type
3
Date filed
1/29/2025, 09:42 PM
Next filing
Feb 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BBNX Class A Common Stock 38.1K Jan 29, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BBNX Employee Stock Option (right to buy) Jan 29, 2025 Class B Common Stock 81.2K $7.51 Direct F1, F2
holding BBNX Employee Stock Option (right to buy) Jan 29, 2025 Class B Common Stock 53.6K $5.10 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to this option shall vest one year after November 14, 2022, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
F2 In accordance with the Issuer's Amended and Restated Certificate of Incorporation, the Issuer's outstanding shares of Class B Common Stock will convert into an equal number of shares of Common Stock immediately prior to the closing of the initial public offering.
F3 The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.